11 Investor presentation First six months of 2025 The high unmet need in diabetes penetration to-date makes unloc Global diabetes and obesity unmet need Globally, ~7% of tota prescriptions a US EUCAN 20 Emerging Mark 16 Estimated prescriptions (in millions) 3 12 US Rest of world • >550 million people live with diabetes globally, with over 90% outside of the US 1 • >900 million people with obesity globally, with around 90% outside of the US 2 8 4 0 2022 2023 1 Diabetes Atlas 11 th edition, 2025, including Type 1 and Type 2 Diabetes. 2 NHANES (2013-2014, 2015-2016, 2017-2020, 2021-2023), U on IQVIA MIDAS, May 2025 data - In ex-US countries, tirzepatide is categorised under GLP-1 diabetes only in IQVIA data, despite ha APAC: Japan, Korea, Oceania and Southeast Asia; AOM: Anti-Obesity Medications; Emerging Markets: mainly Latin America, Middle E Note: the estimated GLP-1 share of prescriptions is based on volume packs from IQVIA. Volume packs are converted into full-year p It is possible for a patient to have a prescription for more than one diabetes treatment.
Download PDF file